Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 First-in-Class CDK4/6 Inhibitor Palbociclib Could Usher in a New Wave of Combination Therapies for HR+, HER2- Breast Cancer.

Literature DB >> 26236140

First-in-Class CDK4/6 Inhibitor Palbociclib Could Usher in a New Wave of Combination Therapies for HR+, HER2- Breast Cancer.

Abstract

Women with hormone receptor-positive, human epidermal growth factor receptor 2- negative breast cancer-the most common subtype-have new options as palbociclib and similar drugs debut. This article outlines the rationale and evidence for their use.

Entities: Disease Gene Species

Year: 2015 PMID： 26236140 PMCID： PMC4517534

Source DB: PubMed Journal: P T ISSN： 1052-1372

17 in total

1. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

Authors: José Baselga; Mario Campone; Martine Piccart; Howard A Burris; Hope S Rugo; Tarek Sahmoud; Shinzaburo Noguchi; Michael Gnant; Kathleen I Pritchard; Fabienne Lebrun; J Thaddeus Beck; Yoshinori Ito; Denise Yardley; Ines Deleu; Alejandra Perez; Thomas Bachelot; Luc Vittori; Zhiying Xu; Pabak Mukhopadhyay; David Lebwohl; Gabriel N Hortobagyi
Journal: N Engl J Med Date: 2011-12-07 Impact factor: 91.245

2. The past, present, and future of cancer incidence in the United States: 1975 through 2020.

Authors: Hannah K Weir; Trevor D Thompson; Ashwini Soman; Bjørn Møller; Steven Leadbetter
Journal: Cancer Date: 2015-02-03 Impact factor: 6.860

3. The cancer drug that almost wasn't.

Authors: Ken Garber
Journal: Science Date: 2014-08-22 Impact factor: 47.728

4. Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy.

Authors: Elizabeth A Mittendorf; Jacqueline S Jeruss; Susan L Tucker; Aparna Kolli; Lisa A Newman; Ana M Gonzalez-Angulo; Thomas A Buchholz; Aysegul A Sahin; Janice N Cormier; Aman U Buzdar; Gabriel N Hortobagyi; Kelly K Hunt
Journal: J Clin Oncol Date: 2011-04-11 Impact factor: 44.544

5. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor.

Authors: Sauveur-Michel Maira; Sabina Pecchi; Alan Huang; Matthew Burger; Mark Knapp; Dario Sterker; Christian Schnell; Daniel Guthy; Tobi Nagel; Marion Wiesmann; Saskia Brachmann; Christine Fritsch; Marion Dorsch; Patrick Chène; Kevin Shoemaker; Alain De Pover; Daniel Menezes; Georg Martiny-Baron; Doriano Fabbro; Christopher J Wilson; Robert Schlegel; Francesco Hofmann; Carlos García-Echeverría; William R Sellers; Charles F Voliva
Journal: Mol Cancer Ther Date: 2011-12-21 Impact factor: 6.261

6. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†.

Authors: M Piccart; G N Hortobagyi; M Campone; K I Pritchard; F Lebrun; Y Ito; S Noguchi; A Perez; H S Rugo; I Deleu; H A Burris; L Provencher; P Neven; M Gnant; M Shtivelband; C Wu; J Fan; W Feng; T Taran; J Baselga
Journal: Ann Oncol Date: 2014-09-17 Impact factor: 32.976

Review 7. Molecular pathways: CDK4 inhibitors for cancer therapy.

Authors: Mark A Dickson
Journal: Clin Cancer Res Date: 2014-05-02 Impact factor: 12.531

8. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.

Authors: Richard S Finn; Judy Dering; Dylan Conklin; Ondrej Kalous; David J Cohen; Amrita J Desai; Charles Ginther; Mohammad Atefi; Isan Chen; Camilla Fowst; Gerret Los; Dennis J Slamon
Journal: Breast Cancer Res Date: 2009 Impact factor: 6.466

9. Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial.

Authors: Howard A Burris; Fabienne Lebrun; Hope S Rugo; J Thaddeus Beck; Martine Piccart; Patrick Neven; Jose Baselga; Katarina Petrakova; Gabriel N Hortobagyi; Anna Komorowski; Edmond Chouinard; Robyn Young; Michael Gnant; Kathleen I Pritchard; Lee Bennett; Jean-Francois Ricci; Hounayda Bauly; Tetiana Taran; Tarek Sahmoud; Shinzaburo Noguchi
Journal: Cancer Date: 2013-03-15 Impact factor: 6.860

Review 10. Signaling through cyclin D-dependent kinases.

Authors: Y J Choi; L Anders
Journal: Oncogene Date: 2013-05-06 Impact factor: 9.867

12 in total

1. Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity.

Authors: Marc Hafner; Caitlin E Mills; Kartik Subramanian; Chen Chen; Mirra Chung; Sarah A Boswell; Robert A Everley; Changchang Liu; Charlotte S Walmsley; Dejan Juric; Peter K Sorger
Journal: Cell Chem Biol Date: 2019-06-06 Impact factor: 8.116

2. Discovery of CDK5 Inhibitors through Structure-Guided Approach.

Authors: Nishat Z Khair; Jimma L Lenjisa; Solomon Tadesse; Malika Kumarasiri; Sunita K C Basnet; Laychiluh B Mekonnen; Manjun Li; Sarah Diab; Matthew J Sykes; Hugo Albrecht; Robert Milne; Shudong Wang
Journal: ACS Med Chem Lett Date: 2019-03-20 Impact factor: 4.345

Review 3. Breast cancer: insights in disease and influence of drug methotrexate.

Authors: Vítor Yang; Maria João Gouveia; Joana Santos; Beate Koksch; Irina Amorim; Fátima Gärtner; Nuno Vale
Journal: RSC Med Chem Date: 2020-05-28

4. Stealth Liposomal Chemotherapeutic Agent for Triple Negative Breast Cancer with Improved Pharmacokinetics.

Authors: Nagavendra Kommineni; David Paul; Raju Saka; Wahid Khan; Satheeshkumar Nanjappan
Journal: Nanotheranostics Date: 2022-08-21

Review 5. Advances in quantitative high-throughput phosphoproteomics with sample multiplexing.

Authors: Joao A Paulo; Devin K Schweppe
Journal: Proteomics Date: 2021-03-30 Impact factor: 3.984

6. Noninvasive PET Imaging of CDK4/6 Activation in Breast Cancer.

Authors: Nicholas Ramos; Jairo Baquero-Buitrago; Zakia Ben Youss Gironda; Youssef Zaim Wadghiri; Thomas Reiner; Fernando E Boada; Giuseppe Carlucci
Journal: J Nucl Med Date: 2019-09-03 Impact factor: 11.082

7. The cell-penetrating FOXM1 N-terminus (M1-138) demonstrates potent inhibitory effects on cancer cells by targeting FOXM1 and FOXM1-interacting factor SMAD3.

Authors: Zhenwang Zhang; Huitong Bu; Jingwei Yu; Yan Chen; Chaozhu Pei; Li Yu; Xiaoqin Huang; Guixiang Tan; Yongjun Tan
Journal: Theranostics Date: 2019-04-25 Impact factor: 11.556

Review 8. Engineered T Cell Therapy for Cancer in the Clinic.

Authors: Lijun Zhao; Yu J Cao
Journal: Front Immunol Date: 2019-10-11 Impact factor: 7.561

9. Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2- Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial.

Authors: Véronique Diéras; Nadia Harbeck; Anil Abraham Joy; Karen Gelmon; Johannes Ettl; Sunil Verma; Dongrui R Lu; Eric Gauthier; Patrick Schnell; Ave Mori; Hope S Rugo; Richard S Finn
Journal: Oncologist Date: 2019-06-19

10. circ_0001588 Induces the Malignant Progression of Hepatocellular Carcinoma by Modulating miR-874/CDK4 Signaling.

Authors: Xiaoyun Bin; Yichen Chen; Jiasheng Ma; Renchao Tang; Zhenrong Zhao; Kangxuan Wang; Jianchu Wang
Journal: J Immunol Res Date: 2021-10-20 Impact factor: 4.818